The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs by Ali, M. Habib et al.
1 
 
The role of lipid geometry in designing liposomes for the solubilisation of poorly 
water soluble drugs 
M. Habib Ali, Behfar Moghaddam, Daniel J. Kirby, Afzal R. Mohammed, Yvonne Perrie,  
Abstract 
Liposomes are well recognised for their ability to improve the delivery of a range of drugs. More commonly they are applied for the delivery of 
water-soluble drugs, but given their structural attributes, they can also be employed as solubilising agents for low solubility drugs as well as 
drug targeting agents. To further explore the potential of liposomes as solubilising agents, we have investigated the role of bilayer packaging in 
promoting drug solubilisation in liposome bilayers. The effect of alkyl chain length and symmetry was investigated to consider if using ‘mis-
matched’ phospholipids could create ‘voids’ within the bilayers, and enhance bilayer loading capacity. Lipid packing was investigated using 
Langmuir studies, which demonstrated that increasing the alkyl chain length enhanced lipid packing, with condensed monolayers forming, 
whilst asymmetric lipids formed less condensed monolayers. However, this more open packing did not translate into improved drug loading, 
with the longer chain, condensed bilayers formed from long-chain, saturated lipids offering higher drug loading capacity. These studies 
demonstrate that liposomes formulated from longer chain, saturated lipids offer enhanced solubilisation capacity. However the molecular size, 
rather than lipophilicity, of the drug to be incorporated was also a key factor dominating bilayer incorporation efficiency. 
1. Introduction 
Liposomes, due to their structural attributes, have been extensively investigated for the delivery of a wide range of 
drugs. Whilst more commonly used for the delivery of water soluble drugs, loading of the drug within the bilayer of 
the vesicles offers the potential of liposomes to act as solubilising agents. Indeed, drugs carried in the liposomal 
bilayer are offered the same advantages as drugs loaded within the aqueous phase of the liposomes: not only can 
the drug be protected from degradation in the body, the pharmacokinetic and tissue distribution patterns of the 
drug can also be modified, and delivery of the drug to the desired site of action can be improved. Thus liposomes are 
able to act not only as a stable solubilising agent, but also offer the potential for drug targeting. For example, studies 
from our laboratory (Daneshpour et al., 2011) have used a liposome delivery system for the site-specific delivery of 
novel transglutaminase (TG) inhibitors to the liver. These TG inhibitors have potential in the treatment of liver 
fibrosis, however they have issues with low solubility and require site specific targeting. By using anionic or neutral-
based liposomes, a TG inhibitor was successfully incorporated into the bilayer of liposomes and delivered specifically 
to the liver (Daneshpour et al., 2011). 
To continue to exploit liposomes as low solubility drug delivery systems, the underpinning parameters that control 
drug loading within the bilayer requires further elucidation. Liposome incorporation efficiency of low solubility drugs 
can be very effective, with key factors such as log P and molecular size potentially influencing drug loading. Yet, 
liposomal incorporation of low water soluble compounds is not only dependent on the physicochemical properties 
of the drug; factors including bilayer composition and bilayer volume also plays a role. Indeed we have previously 
shown (Mohammed et al., 2004) that both the incorporation and release of a sparingly soluble drug (ibuprofen) was 
influenced by the composition of the liposomes, with both the choice of phosphatidylcholine and the cholesterol 
concentration within the bilayer having an impact on drug loading. In particular the ability of the drugs to effectively 
package within the liposome membrane is a dominant factor in the solubilisation of drugs within liposomes. For 
example, whilst cholesterol, through its ability to fill voids within a liposomal membrane, is widely accepted to 
improve bilayer stability (Gregoriadis and Davis, 1979), with early developmental studies (Kirby and Gregoriadis, 
1980) demonstrating that an optimum of 50% mol/mol cholesterol within a liposome formulation increased the 
stability and reduced the permeability of liposomal bilayers, the inclusion of cholesterol in liposomes used as 
solubilising agents requires further consideration. Indeed, studies have shown that whilst the ability of cholesterol to 
effectively package within a liposomal membrane can improve bilayer stability, the presence of cholesterol also 
counteracts the incorporation drugs within liposomal bilayers, and can reduce drug incorporation efficiency 
(Mohammed et al., 2004). The ability to use fatty alcohols as an alternative bilayer stabiliser to cholestero has been 
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shown (Devaraj et al., 2002 and Ali et al., 2010), with the vesicles formed having similar physico-chemical 
characteristics, however, the fatty alcohols had a reduced impact on bilayer drug loading compared to cholesterol 
(Ali et al., 2010). 
In addition, past studies have also suggested that the creation of ‘voids’ within liposomal membranes, by the 
appropriate selection of mis-matched lipids, can alter the physical properties of bilayers, such as fluidity and 
thickness. For example, Kragh-Hansen et al. (1998) discovered that when C12NO (a non-ionic surfactant) was 
formulated with a phospholipid, ‘free volume’ was created within the bilayer due to hydrophobic mismatch via the 
interaction between the shorter C12NO hydrocarbon chain and longer phospholipid alkyl chain. Given that the ability 
to incorporate a drug within a liposomal membrane is determined by appropriate molecular packing, exploiting such 
‘free volume’ to enhance on the incorporation of hydrophobic drugs within liposomal bilayers may be advantageous. 
Therefore the relative significance of the structural characteristics of the membrane (i.e. alkyl chain length of lipid, 
geometry, nature and charge of the head-group and presence of stabiliser) must be established in order to 
understand the mode of action for incorporation of poorly water-soluble drugs in membranes at the molecular level 
(Faucon et al., 1995). It is interesting to also note that whilst nearly all liposomal formulations consider the use of 
symmetrical lipids, many biological lipids have asymmetric alkyl tail chains, where the tail moiety differs by their 
carbon number and degree of saturation, or both (Dan, 2007 and Vilcheze et al., 1996). Therefore, the aim of this 
work was to investigate the role of alkyl chain symmetry and geometry on the capability of liposomes as 
solubilisation agents. The lipids investigated are shown in Fig. 1. 
 
Fig. 1. Structural characteristics of lipids with symmetric and asymmetric alkyl chains lengths. 
2. Materials and methods 
Midazolam and cholesterol were purchased from Sigma–Aldrich, Dorset, UK. Propofol was supplied by MP 
Biomedicals, LLC, Eschwege, Germany. Egg phosphatidylcholine (PC; grade I), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) were purchased from Lipid Products, Epsom, Surrey, UK. Dilignoceroyl phosphatidylcholine 
(DGPC), 1,2-distearoyl-3-phosphatidylgycerol (DSPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP), 
1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP) and 1,2-distearoyl-3-trimethylammonium-propane (DSTAP) 
were supplied by Avanti Polar Lipids, Inc., Alabaster, Alabama, USA. 
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2.1. Langmuir studies 
An automated controlled film balance apparatus (KSV Langmuir Mini-trough, KSV Instruments Ltd., Helsinki, Finland) 
equipped with a platinum Wilhemy plate was used to collect the surface pressure-area isotherms (Ali et al., 2010). 
The size of the trough was 24225.0 mm2 enclosing a total volume of about 220 ml; the sub-phase was filtered 
double-distilled water. The compounds (at fixed total concentration of 1 mg/ml) were dissolved in chloroform and 
20 μl of each solution was spread onto the air/water interface with a Hamilton microsyringe, precise to ±0.2 μl. After 
spreading, the monolayers were left for 10 min for the chloroform to evaporate. Thereafter, the molecules 
underwent constant compression until the required surface pressure was attained. Optimisation work revealed that 
a routine compression speed of 10 mm/min yielded the best isotherms, therefore this speed was maintained 
throughout all monolayer studies. The temperature of the sub-phase was kept constant to 20 ± 1 °C by means of an 
external water bath circulation system. Each experiment was only compressed once and performed at least three 
times with monolayers prepared from different solutions. KSV software (KSV Instruments Ltd., Helsinki, Finland) was 
used for data analysis. 
2.2. Preparation of multilamellar vesicles 
MLV were generated using a technique based on the established film method (Bangham et al., 1965) and modified 
for low solubility drugs (Mohammed et al., 2004). Briefly the lipid were dissolved in a chloroform:methanol (9:1) 
solvent mixture with and without the required amount of drug (1.00 mg), and the solvent evaporated on a rotary 
evaporator to yield a dry film. The film was hydrated with 2 ml of double distilled water to give final lipid 
concentration of 16–24 μmol/ml dependent on formulation. 
2.3. Determination of drug loading in liposomes 
The drug loading of liposomes was determined by measuring the non-incorporated drug present in the hydration 
and wash media after separation of liposomes by centrifugation (Beckman J2 Centrifuge) at 27200 × g for 30 min. All 
samples were diluted appropriately (with respect to each drug solubility values) to avoid drug precipitation. The drug 
content of the supernatant was analysed by UV spectroscopy (Unicam Helios) at the appropriate wavelength for 
each compound (diazepam, 228 nm; ibuprofen, 221 nm; midazolam, 316 nm; phenytoin, 212 nm; propofol, 268 nm; 
rifampicin, 236 nm). This protocol was validated by using a direct method for extraction of drug from liposomes 
established by Fatouros and Antimisiaris (2002). By using this extraction method, we analysed propofol 
concentration within a randomly selected set of liposome preparations, whereby liposomes suspensions (after 
centrifugation to remove non-incorporated drug) were mixed with isopropanol in a 50/50 (v/v) mixture and 
solubilised by vortexing with analysis performed using UV to calculate drug concentration. 
2.4. Drug release studies 
The release rate of drug was determined by incubating drug-loaded vesicles (after separation of non-incorporated 
drug) in 30 ml PBS at 37 °C in a shaking (constant) water bath. Initially, three independent samples each containing 
56 μmol liposomes were prepared. Each homogenous suspension was divided into seven batches, each containing 8 
μmol of preparation. At time intervals of 0, 2, 4, 8, 24, 48 and 72 h, the medium was centrifuged at 27,200 × g for 30 
min. The supernatant was analysed spectrophotometrically at the appropriate wavelength and the amount of drug 
released was assayed. 
2.5. Statistical analysis 
The treatment of the experimental results was based on the analysis average and the analysis of variance (ANOVA). 
Thereafter, Bonferroni's multiple t-test and Student–Newman–Keuls test were used to compare the difference 
between encapsulation efficiency, differences were considered significant when P < 0.05. Each value was obtained 
from at least triplicate samples and expressed as mean ± S.D. 
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3. Results and discussion 
3.1. Investigation of lipid packing of symmetric and asymmetric lipids using monolayer studies 
To consider the molecular packaging of the various lipids in the liposomal bilayer, monolayer studies were initially 
preformed. Whilst not fully representative of a bilayer, the application of monolayer studies has been effectively 
used to explore and identify the interactions of a range of lipids (e.g. Moghaddam et al., 2011a and Moghaddam et 
al., 2011b). In general, the surface pressure for the transition of a monolayer from liquid-expanded to liquid-
condensed phase increased with decreasing chain length (Barnes and Gentle, 2005 and Moghaddam et al., 2011b) 
and this is shown in Fig. 2: for DSPC, the transition from gaseous to liquid expanded phase occurred at an 
approximate molecular area of 58 Å2/molecule while the liquid-expanded to liquid-condensed shift occurred at 
surface pressure of around 5 mN/m, and the film collapsed at ∼60 mN/m (Table 1). The DPPC isotherm is a more 
expanded shape with gaseous to liquid-expanded transition taking place at ∼95 Å2/molecule (Fig. 2) and the switch 
from liquid-expanded to liquid-condensed occurring at a surface pressure of approximately 10 mN/m, and the 
monolayer collapsing at about 65 mN/m (Table 1). The DMPC isotherm is the least condensed; this lipid is in a liquid-
expanded phase at the start of the compression process (∼125 Å2/molecule) and thereon converts to the liquid-
condensed phase at around a surface pressure of 18–20 mN/m. The collapse pressure for DMPC is the lowest 
(around 55 mN/m) compared to DSPC and DMPC. The limiting mean molecular area for DSPC, DPPC and DMPC were 
51.0, 55.8 and 65.5 Å2/molecule, respectively (Table 1). This trend could be attributed to degree of cohesion 
between the chains. In this homologous series of long-chain compounds, the attraction between the chains will 
dictate how closely packed they arrange themselves. DSPC being the longest, will have the strongest chain-chain 
interactions resulting in closely packed chains (Gaines, 1966); this being reflected in its isotherm being nearly straight 
and steep. With decreasing chain length (i.e. DMPC < DPPC < DSPC), this cohesion reduces, yielding films that 
become more ‘gaseous’ (Davies and Rideal, 1963). This work supports the rational that longer chain alkyl lipids 
produce more stable liposomes, since the longer alkyl chains, with stronger cohesion, results in less leakage from the 
aqueous core of liposomes (e.g. Mohammed et al., 2004, Taylor et al., 1990 and Moghaddam et al., 2011b). 
 
Fig. 2.The surface pressure-area isotherms of pure monolayers of DSPC, DPPC, DMPC, MSPC and POPC at the air/water interface (at 20 °C). 
Results are expressed as the means of three experiments ± S.D. 
Lipid category Lipid Extrapolated area at zero pressure (Å2/molecule) Collapse pressure (mN/m) 
Symmetric DSPC 51.0 63.2 
DPPC 55.8 64.3  
DMPC 65.5 56.2  
Asymmetric MSPC 48.5 63.5 
POPC 80.8 44.9  
Table 1. Extrapolated area and collapse pressure of pure DSPC, DPPC, DMPC, MSPC and POPC monolayers at the air–water interface at 
temperature of 20 °C. Results are expressed as the means of three experiments. 
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Considering the asymmetrical lipids, the isotherm for MSPC, which has an average alkyl chain carbon number of 16 
(akin to that of DPPC), bears a strong resemblance to that of DPPC (Fig. 2); gaseous to liquid-expanded transition 
occurred at mean molecular area ∼95 Å2/molecule with monolayer collapsing at surface pressure of about 64 mN/m 
(Table 1). However, the change from liquid-expanded to liquid-condensed for MSPC withstood greater surface 
pressures compared to DPPC and arose at approximately 18 mN/m, suggesting that the presence of one 18 carbon 
alkyl chain was able to impact on monolayer stability. Considering the isotherm for POPC (Fig. 2), it is evident that 
the presence of the unsaturated bond leads to the formation of a less condensed monolayer when compared with 
saturated phospholipids of similar alkyl chain length. This is a result of their structure prohibiting close packaging 
(Gaines, 1966 and Dynarowicz-Latka and Hac-Wydro, 2004) due to the unsaturated bond in the 18-carbon alkyl chain 
of POPC bending the mono-unsaturated alkyl group away from the vertical 16-carbon chain. During compression, the 
protruding alkyl chain induces stearic hindrance, thus increasing the distance between the molecules, making close 
packing more difficult. In addition the number of cis double bonds in the hydrophobic alkyl chain influences its 
geometrical structure, with the actual number of these bonds present being proportional to how bent the chain will 
be ( Hac-Wydro and Wydro, 2007). In the situation of POPC, the increase in intermolecular distance reduces Van der 
Waal attractions between their hydrophobic regions, therefore influencing the condensation of monolayer, lowering 
the collapse pressure and rendering the membrane less stable ( Hac-Wydro and Wydro, 2007). This supports the 
suggestion that the unsaturated chain of POPC inhibits effective packaging of the lipid within the bilayer and 
therefore inhibits the inclusion of drugs within the bilayer, despite its longer alkyl chains lengths, and potentially 
increased hydrophobic volume of the liposomes in comparison to MSPC ( Fig. 2). 
3.2. Drug loading studies: selection of model drugs 
Given the wide selection of drugs which have low solubility we first pre-screened a range of commonly investigated 
drugs (diazepam, ibuprofen, midazolam, phenytoin, propofol and rifampicin) which were investigated in terms of 
their bilayer drug loading using a mulitlamellar vesicle liposome formulation previously investigated (Ali et al., 2010). 
These vesicles were around 5–6 μm in size, as would be expected for MLV prepared by this method (results not 
shown). When drug loading values were plotted against the drug lipophilicity, no apparent trend was observed (Fig. 
3a), at least for the range of drugs considered here. Conversely, plotting MW against encapsulation showed some 
correlation (Fig. 3b), with larger molecules having lower incorporation efficiency; propofol (MW of 178 Da) displayed 
the highest bilayer incorporation of 20.3% mol/mol whilst rifampicin (MW of 823 Da) revealed the least (Fig. 3b). 
When considering molecules of similar lipophilicity, ibuprofen, midazolam and, propofol, with log P values of 3.48, 
3.87 and 3.84, respectively (Wishart, 2006), encapsulation significantly increased in the order of propofol > 
ibuprofen > midazolam, again reflecting their decreasing MW. Therefore it is very possible that MW plays the more 
influential role in dictating levels of drug encapsulation compared to drug lipophilicity, which yielded no clear 
correlation with respect to bilayer drug entrapment. In all the above formulations, the liposomal characteristics in 
terms of vesicle size and zeta potential were not significantly influenced by the drug incorporated, with the MLV 
being around 5–7 μm in diameter with a near neutral zeta potential (results not shown). 
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Fig. 3. The relationship between liposomal (PC:cholesterol, 89:11 mol%) bilayer encapsulation of drug and (a) lipophilicity or (b) molecular 
weight of drug. Results are expressed as the means of at least four experiments ± S.D. Results represent percentage cumulative release of 
initially incorporated propofol and are expressed as the means of four experiments ± S.D. 
3.3. The effect of lipid geometry on drug solubilisation within liposomal bilayers 
To investigate the influence of bilayer area and lipid geometry on the design of liposomes as liposomal solubilising 
agents, liposomes prepared from a series of phospholipids, including POPC and MSPC, which are structurally 
asymmetrical in terms of their alkyl chain lengths, were investigated and compared with symmetrical alkyl chain 
lipids, DGPC, DSPC, DPPC and DMPC. Each formulation was prepared with 11 molar % cholesterol, and the drug 
loading of propofol and midazolam (which offered a high and low entrapment respectively in initial studies; Fig. 3) 
was considered. 
Considering the effect of alkyl chain length, there is a general tendency of increasing propofol and midazolam 
bilayer-incorporation with increased lipid chain length in the order of DGPC > DSPC > DMPC ≈ DPPC > PC (Fig. 4a). 
This correlates with previous work investigating the solubilisation of ibuprofen in liposomes (Mohammed et al., 
2004) that revealed a trend of increasing encapsulation levels of water-insoluble ibuprofen with increasing lipid 
chain length in the order of DGPC > DSPC > DMPC > PC, with drug loading being improved by approximately 50% 
when DGPC was substituted for PC. In early studies, Gregoriadis (1973) showed that the longer alkyl chain DPPC was 
superior to PC in enhancing encapsulation of actinomycin D, a slightly water-soluble antibiotic and this trend does 
not appear to be exclusive to liposomes: Ismail et al. (1970) established improved solubilities of certain barbiturates 
in micelles of polysorbates of increasing hydrophobic chain length. This increasing drug loading, with increased alkyl 
chain length, has been attributed to the increased bilayer lipophilic area within systems formed by these longer lipid 
bilayers for the hydrophobic drug to accommodate within (Dan, 2007). 
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Fig. 4. The influence of long-chain symmetric and asymmetric lipids on midazolam or propofol encapsulation. (A) Liposomes were prepared 
from a combination of PC, DMPC, DPPC, DSPC, DGPC, POPC or MSPC (89 mol%) with 11 total molar % cholesterol and drug loading in a total 
lipid concentration of 18 μmol. (B) Diagram proposing the possible loss of hydrophopic region in an asymmetric lipid bilayer due to a 
‘mismatch’ interaction between phospholipids possessing two hydrocarbon side-chains of differing length resulting in diameter reduction 
(right) when compared to a bilayer containing a symmetrical lipid (left) (d = diameter). (C) A comparison of midazolam encapsulation by 
MSPC:chol or DMPC:chol (89:11 mol%) liposomes prepared using increasing amounts of cholesterol. Results are expressed as the means of 
three experiments ± S.D. 
When considering the asymmetrical PC derivatives, MSPC and POPC provided significantly (p < 0.05) lower 
incorporation rates for propofol when compared to their symmetrical counterparts, DSPC and DMPC ( Fig. 4a). 
Similarly, incorporation studies using midazolam suggest that symmetrical PC derivatives provide significantly higher 
(p < 0.05) encapsulation of midazolam when compared their asymmetrical counterparts ( Fig. 4a). This generally 
reduced drug-loading by liposomes formulated from asymmetrical lipids maybe attributed to bilayer formation via a 
mismatch interaction between alkyl side-chains of asymmetric lipids, therefore reducing the overall hydrophobic 
area available for hydrophobic drug interaction, when compared to that of symmetric lipid bilayers ( Fig. 4b). The 
decrease in drug loading capacity of shorter alkyl chain lipid bilayers has been previously shown with incorporation 
of ibuprofen ( Mohammed et al., 2004) and is similar to previously reported results with the micellar solubilisation of 
drugs such as barbiturates ( Arnarson and Elworthy, 1980 and Ismail et al., 1970). This is further supported by the 
finding that the presence of cholesterol within the liposome formulation has a greater impact on the MSPC 
formulation compared to the DMPC formulation ( Fig. 4c) suggesting the competitive space-filling action of 
cholesterol is more notable in the decreased bilayer volume of the MSPC liposomes. Therefore the reduced 
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hydrophobic region of the MSPC combined with the competing action of cholesterol for packaging within the bilayer 
reduces bilayer drug loading ( Ali et al., 2010, Moghaddam et al., 2011a and Moghaddam et al., 2011b). 
Given that POPC has longer alkyl chains compared to MSPC it might be expected to offer higher drug loading if the 
above proposal was applied, however Fig. 4a does not confirm this. The reduced drug-entrapment for POPC vesicles 
could be attributed to the single unsaturated bond it carries on the longer (C18) hydrocarbon chain. Past studies 
(Yoshioka et al., 1994) report that sorbitan monooleate (C9=9) niosomes encapsulate lower amounts of solute than its 
alkyl analogue, C18 sorbitan monoester niosomes. This may be due to the fact that the presence of alkyl chain 
unsaturation is said to enhance chain fluidity and hence bilayer permeability (Uchegbu and Florence, 1995 and 
Devaraj et al., 2002). Investigations using a Langmuir trough by Hac-Wydro and Wydro (2007) showed that the 
inclusion of a saturated fatty acid to a phospholipid/cholesterol membrane makes the model system more rigid, 
whereas the presence of an unsaturated fatty acid enhances its fluidity. Additionally, it is recognised that cholesterol 
has lower solubility in membranes with polyunsaturated acyl chain moieties (Bennati et al., 2007 and Brzustowicz et 
al., 2002). This can be rationalised by the fact that polyunsaturated chains display a jagged shape that does not pack 
adequately with the smooth surface of cholesterol (Bennati et al., 2007), thereby not rigidifying a bilayer as well as 
sufficiently packed cholesterol in a saturated bilayer would. Therefore, whilst the proposal that POPC liposomal 
bilayers may package in a way to create free space which could support bilayer drug loading (Kragh-Hansen et al., 
1998), the results in Fig. 4 do not support this and it may be considered that the unsaturated chain of POPC inhibits 
packaging of drugs within the bilayer in a similar concept to that proposed by Bennati et al. (2007) for cholesterol. 
Considering the sizes of the liposomes, encapsulating midazolam or propofol there is no notable difference between 
the various formulations prepared (Supplementary data; Table 1). Similarly the zeta potential was not significantly 
influenced by the lipid geometry as would be expected given all the lipids have the same head-group 
(Supplementary data; Table 1). 
Given that past studies have shown that physical properties of the bilayer, such as fluidity and thickness, can be 
altered by creating ‘voids’ in the phospholipid bilayer, with Kragh-Hansen et al. (1998) demonstrating that when 
C12NO (a non-ionic surfactant) was formulated with a phospholipid, voids (‘free volume’) were formed within the 
bilayer due to hydrophobic mismatch via the interaction between the shorter C12NO hydrocarbon chain and longer 
phospholipid alkyl chain. This was further explored by combining long-chain symmetric and asymmetric lipids and 
DSPC was combined with POPC or MSPC, and DPPC with POPC or MSPC. 
All formulations were prepared containing 11 total molar % cholesterol (for full details on composition, see 
Supplementary Table). The results from Fig. 5 suggest that possible ‘voids’ created in the bilayer by a mismatch 
arrangement of phospholipids did not give a major improvement on drug solubilisation, with liposomes formulated 
from DSPC:cholesterol showing the highest solubilisation capacity. Similarly there was no notable difference in size 
or zeta potential in the various formulations (Supplementary Table 1). 
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Fig. 5. The influence of combining long-chain symmetric and asymmetric lipids on drug encapsulation. Liposomes were prepared from DPPC, 
DSPC, MSPC or POPC and cholesterol (89:11 mol%) or in a combination of DSPC or DPPC (44.5 mol%) with POPC or MSPC (44.5 mol%) and 
cholesterol (11 mol%) with drug encapsulation in a total lipid concentration of 18 μmol drug. Results are expressed as the means of four 
independent experiments ± S.D. 
3.4. The influence of charged lipid on drug solubilisation within lipid bilayers 
Having previously shown that the presence of charged lipids influenced the solubilisation of ibuprofen, and that the 
presence of charged lipids may influence bilayer packing (Mohammed et al., 2004), this was further explored with 
propofol, using a series of cationic and anionic lipids. Liposomes were prepared from cationic lipids (DSTAP, C18 alkyl 
chain length; DPTAP, C16 alkyl chain length; DMTAP, C14 alkyl chain length) and their ability to solubilise propofol was 
compared against their neutral (DSPC, DPPC, and DMPC) or anionic (DSPG, DPPG, DMPG) phospholipid analogues. All 
formulations contained 11 molar % cholesterol as per previous studies. 
Investigations of positively charged lipids revealed a trend of increasing liposome incorporation of propofol with an 
increase in alkyl chain length in the order of DSTAP > DPTAP > DMTAP (p < 0.05) ( Fig. 6a). This trend appears to 
correlate with their corresponding neutral lipid derivatives ( Fig. 4a) suggesting that, irrespective of the surfactant 
charge, the solubilisation of propofol within the bilayer incrementally increases with increasing surfactant chain 
length. A similar conclusion was published by Rangel-Yagui et al. (2005) who investigated the solubilisation of 
ibuprofen in micellar solutions prepared from three different surfactants (sodium dodecyl sulphate, 
dodecyltrimethylammonium bromide and n-dodecyl octa(ethylene oxide)). 
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Fig. 6. (a) Encapsulation of propofol by charged liposomes and their neutral phospholipid analogue all prepared with 89% phospholipid and 
11% cholesterol. (b) The vesicle surface charge of charged vesicles compared against the zeta potential of their neutral counterpart. (c) Effect 
of alkyl chain length of positively charged TAP series on bilayer release of propofol. (d) Effect of vesicle surface charge on rate of propofol 
release. Results are expressed as the means of four independent experiments ± S.D. 
The results in Fig. 6 also revealed an improvement in propofol-solubilisation by positively charged liposomes when 
compared with their neutral and negatively charged counterparts (Fig. 6a and b). DSTAP and DPTAP encapsulated a 
significantly (p < 0.05) greater quantity of drug than their neutral analogues, DSPC and DPPC, respectively, with 
DMTAP revealing no significant difference in propofol-loading compared with DMPC. The increase in drug-
incorporation by the cationic charged liposomes could be due to intermolecular π-cation interaction between the 
aromatic ring of propofol and the positively charged nitrogen on the head-group of the cationic lipids, a non-bonded 
interaction that has attracted considerable attention ( Garau et al., 2004). Benzene is non-polar, since no single 
carbon atom is more negatively charged than the other carbon atoms, there is no net dipole moment. However, the 
distribution of electrons is uneven throughout the molecule resulting in a state termed ‘quadrupole’ where there 
exists more negative charge both above and below the hexagonal plane of carbons ( Ma and Dougherty, 1997). 
Empirical evidence suggests that this kind of interaction exist and is relatively strong ( Garau et al., 2004). X-ray 
crystal analysis by Hamada et al. (2006) reveal the molecular assembly of thiacalix[6]arene via π-cation interaction 
between the aromatic ring of thiacalix[6]arene and a positively charged group, such as nitrogen of 
dimethylformamide. Furthermore, Dougherty and Stauffer (1990) proposed that the π-cation interaction is 
responsible for the binding of acetylcholine to its deactivating enzyme, acetylcholinesterase. 
3.5. Solubilised drug release from the liposomal carriers 
To consider how the formulation of the vesicles influenced drug release rates, three formulations, consisting of 
DMTAP, DPTAP or DSTAP and including 11 mol% cholesterol, were incubated in PBS at 37 °C for up to 72 h and their 
release of retained propofol examined. Results (Fig. 6c) suggest that alkyl chain length of cationic lipid series 
(DMTAP, DPTAP and DSTAP) does not appear to influence the cumulative release of propofol. This is in contrast to 
the outcome observed for neutral lipid formulations previously reported (Ali et al., 2010). Therefore, the impact of 
the charge-headgroups was also considered. Fig. 6d demonstrates that the cumulative drug released at 72 h varied 
between the DSPC, DSTAP and DSPG preparations. Of the three formulations, drug release from cationic DSTAP 
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formulation was the highest and the slowest release rate was noted for the neutral DSPC preparation, suggesting 
that both charge and alkyl chain length are contributing to the release rates. The effect of charge on drug 
permeability has been previously documented; results collated by Nounou et al. (2006) revealed that positively 
charged liposomes exhibited the fastest release compared with neutral and negatively charged preparations. 
Furthermore, Mohammed et al. (2004) demonstrated that the inclusion of 9 mol% stearylamine (positively charged) 
or dicetylphosphate (negatively charged) induced significantly more release of ibuprofen compared to neutral 
liposomes. Given the above findings, it is clear that electrostatic drug-bilayer interactions, in combination with lipid 
packaging, needs consideration in bilayer drug release. 
4. Conclusion 
Liposomes as solubilising agents can play a key role in addressing the need for improved delivery of low solubility 
drugs. Whilst already clinically exploited for the solubilisation and delivery of the Amphotericin B, additional 
understanding of the parameters which dictate incorporation of the drugs within bilayers is required. Given that the 
ability for drugs to package within these bilayers is a key attribute, we have investigated if the development of 
bilayers from ‘mis-matched’ lipids to create ‘free space’ within the bilayers can enhance drug loading. Langmuir 
studies revealed that both the length of alkyl chain and the presence of unsaturated bonds influenced lipid 
packaging in a monolayer, with shorter chain lipids and lipids with asymmetric lipid chains showing less condensed 
monolayers, suggesting these lipids may offer more space for solubilisation for drugs within liposomal bilayers. 
However, of the liposomal formulations studied, formulations containing longer alkyl chain length lipids (DSPC, DSPG 
and DSTAP) gave higher drug solubilisation and the use of lipids with asymmetric alkyl chains did not enhance 
solubilisation efficiency. This confirms that the proposal of creating voids within the liposomal bilayer is not 
advantageous in designing liposomes as solubilisation agents despite drug molecular size being a key factor in drug 
loading capacity of liposomes. 
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